

Table 10.6g
Immunosuppression Use for Maintenance Between Discharge
and One Year Following Transplantation, 1998 to 2007
Recipients with Intestine Transplants

| | Year of Transplant | | | | | | | | | |
|-----------------------------------------------------|--------------------|--------|--------|--------|--------|-------|-------|-------|-------|-------|
| | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 |
| Transplants | 70 | 73 | 82 | 113 | 107 | 116 | 152 | 178 | 175 | 198 |
| Tx with Follow-up Immunosuppression Info | 34 | 37 | 55 | 69 | 73 | 88 | 113 | 130 | 120 | 139 |
| Corticosteroids | | | | | | | | | | |
| Any in Category | 97.1% | 100.0% | 100.0% | 85.5% | 90.4% | 83.0% | 78.8% | 79.2% | 86.7% | 85.6% |
| Steroids | 97.1% | 100.0% | 100.0% | 85.5% | 90.4% | 83.0% | 78.8% | 79.2% | 86.7% | 85.6% |
| Cyclosporine | | | | | | | | | | |
| Any in Category | 2.9% | 2.7% | 0.0% | 0.0% | 1.4% | 0.0% | 0.9% | 1.5% | 1.7% | 1.4% |
| Sandimmune | 0.0% | 2.7% | 0.0% | 0.0% | 1.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.7% |
| Neoral | 2.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.9% | 0.8% | 1.7% | 0.7% |
| Gengraf | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.8% | 0.0% | 0.0% |
| Tacrolimus | | | | | | | | | | |
| Any in Category | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 98.9% | 97.3% | 98.5% | 98.3% | 99.3% |
| Tacrolimus | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 98.9% | 97.3% | 98.5% | 98.3% | 97.1% |
| Everolimus | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.2% |
| Antimetabolites | | | | | | | | | | |
| Any in Category | 41.2% | 37.8% | 14.5% | 15.9% | 11.0% | 10.2% | 12.4% | 20.0% | 16.7% | 18.7% |
| Mycophenolate Mofetil | 35.3% | 21.6% | 14.5% | 2.9% | 9.6% | 10.2% | 8.0% | 13.8% | 13.3% | 12.9% |
| Azathioprine | 5.9% | 16.2% | 0.0% | 13.0% | 1.4% | 0.0% | 4.4% | 6.2% | 3.3% | 5.8% |
| mTOR Inhibitors | | | | | | | | | | |
| Any in Category | 0.0% | 21.6% | 69.1% | 24.6% | 28.8% | 15.9% | 22.1% | 23.8% | 19.2% | 10.8% |
| Sirolimus | 0.0% | 21.6% | 69.1% | 24.6% | 28.8% | 15.9% | 22.1% | 23.8% | 19.2% | 10.8% |
| Everolimus | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Percentages are calculated based on the total number of patients with any immunosuppression use between discharge and one year following transplantation.
 Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.